Nikhil Anand
A5087050607- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Inflammatory Bowel Disease
- Peripheral Neuropathies and Disorders
- Immunodeficiency and Autoimmune Disorders
- Cancer Immunotherapy and Biomarkers
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Pediatric Hepatobiliary Diseases and Treatments
Imperial College London
2022-2024
BackgroundCOVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive treatments were associated and T-cell IBD a third dose.MethodsVIP was multicentre, prospective, case-control study done nine centres the UK. recruited immunosuppressed non-immunosuppressed healthy individuals. All participants aged 18 years older. The control group had no...
Background: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking infliximab or tofacitinib after two vaccine doses. We sought to determine whether immunosuppressive treatments were associated and T cell a third dose. Methods: 352 adults (72 healthy controls 280 IBD) from the prospectively recruited study cohort sampled 28-49 days dose of SARS-CoV-2 vaccine. IBD medications studied included thiopurines (n=65), (n=46),...
Abstract Background Patients with Inflammatory bowel disease (IBD) receiving anti-TNF or JAK-inhibitor therapy have attenuated responses to COVID-19 vaccination. We aimed determine how IBD treatments affect neutralising antibody against the currently dominant Omicron BA.4/5 variants. Methods prospectively recruited 329 adults (68 healthy controls (HC) and 261 IBD) who had received three doses of vaccine at nine UK centres. The population was established (>12 weeks therapy) on either...